{"id":41212,"date":"2026-02-04T11:00:00","date_gmt":"2026-02-04T14:00:00","guid":{"rendered":"https:\/\/www.grupomedcof.com.br\/blog\/?p=41212"},"modified":"2026-01-30T08:59:08","modified_gmt":"2026-01-30T11:59:08","slug":"carcinoma-hepatocelular","status":"publish","type":"post","link":"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/","title":{"rendered":"Carcinoma Hepatocelular: do rastreio ao transplante"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_74 counter-hierarchy ez-toc-counter ez-toc-transparent ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Sum\u00e1rio<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabela de conte\u00fado\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#Fisiopatologia_e_Fatores_de_Risco\" >Fisiopatologia e Fatores de Risco<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#Rastreio_Screening\" >Rastreio (Screening)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#Diagnostico_nao_invasivo\" >Diagn\u00f3stico n\u00e3o invasivo<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#Classificacao_LI-RADS_Liver_Imaging_Reporting_and_Data_System\" >Classifica\u00e7\u00e3o LI-RADS (Liver Imaging Reporting and Data System)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#Estadiamento_e_Conduta_Sistema_BCLC\" >Estadiamento e Conduta (Sistema BCLC)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#Estagio_0_Muito_Precoce_e_A_Precoce_%E2%80%93_Intencao_Curativa\" >Est\u00e1gio 0 (Muito Precoce) e A (Precoce) \u2013 Inten\u00e7\u00e3o Curativa<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#A_Resseccao_Hepatectomia\" >A. Ressec\u00e7\u00e3o (Hepatectomia):<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#B_Transplante_Hepatico\" >B. Transplante Hep\u00e1tico:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#C_Ablacao_por_Radiofrequencia\" >C. Abla\u00e7\u00e3o por Radiofrequ\u00eancia:<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#Estagio_B_Intermediario\" >Est\u00e1gio B (Intermedi\u00e1rio)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#Estagio_C_Avancado\" >Est\u00e1gio C (Avan\u00e7ado)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#Estagio_D_Terminal\" >Est\u00e1gio D (Terminal)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#Tratamento_do_Carcinoma\" >Tratamento do Carcinoma&nbsp;<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#Terapias_Curativas_Estadios_0_e_A\" >Terapias Curativas (Est\u00e1dios 0 e A)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#Terapias_Locorregionais_Estadio_B_%E2%80%93_Intermediario\" >Terapias Locorregionais (Est\u00e1dio B &#8211; Intermedi\u00e1rio)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#Terapia_Sistemica_Estadio_C_%E2%80%93_Avancado\" >Terapia Sist\u00eamica (Est\u00e1dio C &#8211; Avan\u00e7ado)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#Radioterapia_O_%E2%80%9CNovo%E2%80%9D_Jogador\" >Radioterapia: O &#8220;Novo&#8221; Jogador<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#Seja_um_MedCofer\" >Seja um MedCofer!<\/a><\/li><\/ul><\/nav><\/div>\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509-1024x576.jpg\" alt=\"\" class=\"wp-image-41222\" srcset=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509-1024x576.jpg 1024w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509-300x169.jpg 300w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509-768x432.jpg 768w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509-1536x864.jpg 1536w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509-747x420.jpg 747w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509-150x84.jpg 150w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509-696x392.jpg 696w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509-1068x601.jpg 1068w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509.jpg 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">O <strong>Carcinoma Hepatocelular<\/strong> \u00e9 o tumor maligno prim\u00e1rio mais comum do f\u00edgado e a <strong>terceira principal causa de morte por c\u00e2ncer no mundo<\/strong>. Diferente de outras neoplasias, geralmente surge em um &#8220;solo f\u00e9rtil&#8221;: o <strong>f\u00edgado cirr\u00f3tico. <\/strong>O manejo deste paciente exige um equil\u00edbrio delicado entre tratar o c\u00e2ncer e<strong>preservar a fun\u00e7\u00e3o hep\u00e1tica restante<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fisiopatologia-e-fatores-de-risco\"><span class=\"ez-toc-section\" id=\"Fisiopatologia_e_Fatores_de_Risco\"><\/span><strong>Fisiopatologia e Fatores de Risco<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A regra pr\u00e1tica \u00e9 clara: <strong>90% dos casos de CHC ocorrem em pacientes cirr\u00f3ticos<\/strong>. A inflama\u00e7\u00e3o cr\u00f4nica e a regenera\u00e7\u00e3o nodular incessante criam o ambiente prop\u00edcio para muta\u00e7\u00f5es.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As principais etiologias incluem:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cirrose (Qualquer causa):<\/strong> O principal fator de risco isolado.<\/li>\n\n\n\n<li><strong>Hepatite B (HBV):<\/strong> Possui um mecanismo de carcinog\u00eanese \u00fanico. O v\u00edrus B integra seu DNA ao genoma do hepat\u00f3cito, podendo causar CHC <strong>mesmo na aus\u00eancia de cirrose<\/strong>.<\/li>\n\n\n\n<li><strong>NASH (Esteatohepatite N\u00e3o Alco\u00f3lica):<\/strong> Com a epidemia de obesidade, tem se tornado uma causa emergente e preocupante, muitas vezes diagnosticada tardiamente.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-rastreio-screening\"><span class=\"ez-toc-section\" id=\"Rastreio_Screening\"><\/span><strong>Rastreio (Screening)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">O objetivo \u00e9 detectar a les\u00e3o em est\u00e1gio curativo (assintom\u00e1tico).<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>P\u00fablico-Alvo:<\/strong> Todo paciente cirr\u00f3tico (Child A e B; Child C apenas se estiver em lista de transplante) e portadores de Hepatite B cr\u00f4nica (especialmente asi\u00e1ticos &gt;40 anos e africanos).<\/li>\n\n\n\n<li><strong>M\u00e9todo:<\/strong> Ultrassonografia (USG) de Abdome a cada <strong>6 meses<\/strong>.<\/li>\n\n\n\n<li><strong>Papel da Alfa-fetoprote\u00edna (AFP):<\/strong> Embora controverso internacionalmente, no Brasil \u00e9 utilizado como adjuvante.\n<ul class=\"wp-block-list\">\n<li><em>AFP &gt; 400 ng\/ml:<\/em> Altamente sugestivo de CHC em pacientes de risco.<\/li>\n\n\n\n<li><em>AFP &gt; 1.000 ng\/ml:<\/em> Sinal de p\u00e9ssimo progn\u00f3stico, sugerindo invas\u00e3o vascular ou micro-met\u00e1stases (pode contraindicar o transplante).<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-diagnostico-nao-invasivo\"><span class=\"ez-toc-section\" id=\"Diagnostico_nao_invasivo\"><\/span><strong>Diagn\u00f3stico n\u00e3o invasivo<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">O CHC \u00e9 uma das poucas neoplasias que pode ser diagnosticada <strong>sem bi\u00f3psia<\/strong>, desde que o paciente seja de risco (cirr\u00f3tico\/HBV) e apresente o padr\u00e3o vascular t\u00edpico em exame din\u00e2mico (TC ou Resson\u00e2ncia Magn\u00e9tica trif\u00e1sica).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>O Padr\u00e3o T\u00edpico (&#8220;Washout&#8221;):<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">O f\u00edgado recebe sangue majoritariamente da veia porta (75%), mas o CHC, como todo tumor, cria neovasos arteriais.<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Fase Arterial:<\/strong> A les\u00e3o brilha intensamente (<strong>Hipervasculariza\u00e7\u00e3o<\/strong>), pois recebe sangue da art\u00e9ria hep\u00e1tica enquanto o resto do f\u00edgado ainda est\u00e1 &#8220;esperando&#8221; o sangue portal.<\/li>\n\n\n\n<li><strong>Fase Venosa\/Portal:<\/strong> O contraste sai rapidamente do tumor (<strong>Washout<\/strong> ou lavagem), tornando a les\u00e3o hipodensa em rela\u00e7\u00e3o ao f\u00edgado, que agora est\u00e1 brilhando com o contraste portal.<\/li>\n\n\n\n<li><strong>Pseudoc\u00e1psula:<\/strong> Realce perif\u00e9rico na fase tardia.<\/li>\n<\/ol>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"975\" height=\"343\" src=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-79.png\" alt=\"\" class=\"wp-image-41213\" srcset=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-79.png 975w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-79-300x106.png 300w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-79-768x270.png 768w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-79-150x53.png 150w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-79-696x245.png 696w\" sizes=\"auto, (max-width: 975px) 100vw, 975px\" \/><figcaption class=\"wp-element-caption\">Fase arterial com tumora\u00e7\u00e3o hipervascular em f\u00edgado (esquerda), e fase venosa com Wash-Out. Tomografia ou Resson\u00e2ncia Magn\u00e9tica contrastadas. Fonte: Radiopaedia. Case courtesy of Natalie Yang<\/figcaption><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"887\" height=\"382\" src=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-80.png\" alt=\"\" class=\"wp-image-41214\" srcset=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-80.png 887w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-80-300x129.png 300w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-80-768x331.png 768w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-80-150x65.png 150w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-80-696x300.png 696w\" sizes=\"auto, (max-width: 887px) 100vw, 887px\" \/><figcaption class=\"wp-element-caption\">Tomografia ou Resson\u00e2ncia Magn\u00e9tica contrastadas. Fonte: Radiopaedia. Case courtesy of Natalie Yang.<\/figcaption><\/figure>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"465\" height=\"332\" src=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-81.png\" alt=\"\" class=\"wp-image-41215\" srcset=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-81.png 465w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-81-300x214.png 300w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-81-150x107.png 150w\" sizes=\"auto, (max-width: 465px) 100vw, 465px\" \/><figcaption class=\"wp-element-caption\">Realce perif\u00e9rico (rim enhancement) Axial T1 Arterial. Fonte: Radiopaedia. Case courtesy of Natalie Yang<\/figcaption><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"471\" height=\"330\" src=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-82.png\" alt=\"\" class=\"wp-image-41216\" srcset=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-82.png 471w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-82-300x210.png 300w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-82-150x105.png 150w\" sizes=\"auto, (max-width: 471px) 100vw, 471px\" \/><figcaption class=\"wp-element-caption\">Les\u00e3o avan\u00e7ada com trombose tumoral do ramo portal direito. Fonte: Radiopaedia. Case courtesy of Natalie Yang.<\/figcaption><\/figure>\n<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-classificacao-li-rads-liver-imaging-reporting-and-data-system\"><span class=\"ez-toc-section\" id=\"Classificacao_LI-RADS_Liver_Imaging_Reporting_and_Data_System\"><\/span><strong>Classifica\u00e7\u00e3o LI-RADS (Liver Imaging Reporting and Data System)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>LI-RADS 3:<\/strong> Probabilidade intermedi\u00e1ria.<\/li>\n\n\n\n<li><strong>LI-RADS 4:<\/strong> Prov\u00e1vel CHC.<\/li>\n\n\n\n<li><strong>LI-RADS 5:<\/strong> <strong>Definitivamente CHC.<\/strong> (Trata-se sem bi\u00f3psia).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-estadiamento-e-conduta-sistema-bclc\"><span class=\"ez-toc-section\" id=\"Estadiamento_e_Conduta_Sistema_BCLC\"><\/span><strong>Estadiamento e Conduta (Sistema BCLC)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">O sistema de Barcelona (BCLC) \u00e9 o padr\u00e3o-ouro pois considera: <strong>Tamanho do Tumor + Fun\u00e7\u00e3o Hep\u00e1tica (Child) + Performance Status (ECOG).<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-estagio-0-muito-precoce-e-a-precoce-intencao-curativa\"><span class=\"ez-toc-section\" id=\"Estagio_0_Muito_Precoce_e_A_Precoce_%E2%80%93_Intencao_Curativa\"><\/span><strong>Est\u00e1gio 0 (Muito Precoce) e A (Precoce) \u2013 Inten\u00e7\u00e3o Curativa<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pacientes com n\u00f3dulo \u00fanico ou at\u00e9 3 n\u00f3dulos &lt; 3cm, com fun\u00e7\u00e3o preservada. Aqui temos o grande dilema: <strong>Ressec\u00e7\u00e3o ou Transplante?<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"837\" height=\"485\" src=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-83.png\" alt=\"\" class=\"wp-image-41217\" srcset=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-83.png 837w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-83-300x174.png 300w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-83-768x445.png 768w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-83-725x420.png 725w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-83-150x87.png 150w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-83-696x403.png 696w\" sizes=\"auto, (max-width: 837px) 100vw, 837px\" \/><figcaption class=\"wp-element-caption\">Fluxograma de conduta com pacientes precoce e muito precoce. Fonte: Acervo de aulas do Grupo MedCof.&nbsp;<\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-a-resseccao-hepatectomia\"><span class=\"ez-toc-section\" id=\"A_Resseccao_Hepatectomia\"><\/span><strong>A. Ressec\u00e7\u00e3o (Hepatectomia):<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ideal para n\u00f3dulo \u00fanico em paciente com fun\u00e7\u00e3o hep\u00e1tica excelente.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>Crit\u00e9rios de Seguran\u00e7a (obrigat\u00f3rios para n\u00e3o matar o paciente de insufici\u00eancia hep\u00e1tica):<\/em>\n<ol class=\"wp-block-list\">\n<li>Aus\u00eancia de Hipertens\u00e3o Portal (Sem varizes esof\u00e1gicas, plaquetas &gt; 100.000).<\/li>\n\n\n\n<li>Bilirrubinas normais.<\/li>\n\n\n\n<li>Remanescente hep\u00e1tico adequado.<\/li>\n<\/ol>\n<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-b-transplante-hepatico\"><span class=\"ez-toc-section\" id=\"B_Transplante_Hepatico\"><\/span><strong>B. Transplante Hep\u00e1tico:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c9 a melhor op\u00e7\u00e3o oncol\u00f3gica, pois remove o tumor e a doen\u00e7a de base (cirrose).<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Crit\u00e9rios de Mil\u00e3o:<\/strong> Para entrar na fila, o paciente deve ter:\n<ul class=\"wp-block-list\">\n<li>1 n\u00f3dulo $\\le$ 5 cm; OU<\/li>\n\n\n\n<li>At\u00e9 3 n\u00f3dulos, nenhum maior que 3 cm.<\/li>\n\n\n\n<li>Aus\u00eancia de invas\u00e3o vascular ou met\u00e1stases.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Crit\u00e9rio de Desempate (MELD):<\/strong> Pacientes com CHC dentro de Mil\u00e3o recebem pontos extras no MELD (iniciam com 20, sobem para 24 em 3 meses, depois 29) para &#8220;furar a fila&#8221;, devido ao risco de progress\u00e3o tumoral.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-c-ablacao-por-radiofrequencia\"><span class=\"ez-toc-section\" id=\"C_Ablacao_por_Radiofrequencia\"><\/span><strong>C. Abla\u00e7\u00e3o por Radiofrequ\u00eancia:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Op\u00e7\u00e3o curativa para n\u00f3dulos pequenos (&lt; 3cm) em pacientes que n\u00e3o toleram cirurgia.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-estagio-b-intermediario\"><span class=\"ez-toc-section\" id=\"Estagio_B_Intermediario\"><\/span><strong>Est\u00e1gio B (Intermedi\u00e1rio)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pacientes com m\u00faltiplos n\u00f3dulos, mas sem invas\u00e3o vascular, Child A\/B.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Conduta:<\/strong> <strong>Quimioemboliza\u00e7\u00e3o Transarterial (TACE).<\/strong><\/li>\n\n\n\n<li><em>Mecanismo:<\/em> Injeta-se quimioter\u00e1pico diretamente na art\u00e9ria que nutre o tumor e, em seguida, oclui-se o vaso (emboliza\u00e7\u00e3o). O tumor sofre por a\u00e7\u00e3o da droga e por isquemia.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"509\" height=\"398\" src=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-84.png\" alt=\"\" class=\"wp-image-41218\" srcset=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-84.png 509w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-84-300x235.png 300w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-84-150x117.png 150w\" sizes=\"auto, (max-width: 509px) 100vw, 509px\" \/><figcaption class=\"wp-element-caption\">Fluxograma de conduta com pacientes intermedi\u00e1rios. Fonte: Acervo de aulas do Grupo MedCof.<\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Estagio_C_Avancado\"><\/span><strong>Est\u00e1gio C (Avan\u00e7ado)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pacientes com invas\u00e3o da veia porta, met\u00e1stases extra-hep\u00e1ticas ou sintomas constitucionais (ECOG 1-2).<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Conduta:<\/strong> Terapia Sist\u00eamica.<\/li>\n\n\n\n<li><em>Padr\u00e3o Atual:<\/em> Imunoterapia (<strong>Atezolizumab<\/strong>) associada a antiangiog\u00eanico (<strong>Bevacizumab<\/strong>). Essa combina\u00e7\u00e3o superou o antigo Sorafenibe, oferecendo sobrevida global mediana superior a 17 meses.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"506\" height=\"497\" src=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-85.png\" alt=\"\" class=\"wp-image-41219\" srcset=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-85.png 506w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-85-300x295.png 300w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-85-428x420.png 428w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-85-150x147.png 150w\" sizes=\"auto, (max-width: 506px) 100vw, 506px\" \/><figcaption class=\"wp-element-caption\">Fluxograma de conduta com pacientes avan\u00e7ados. Fonte: Acervo de aulas do Grupo MedCof.<\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Estagio_D_Terminal\"><\/span><strong>Est\u00e1gio D (Terminal)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pacientes com disfun\u00e7\u00e3o hep\u00e1tica grave (Child C) ou performance ruim (acamados).<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Conduta:<\/strong> Cuidados Paliativos (<em>Best Supportive Care<\/em>).<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"408\" height=\"235\" src=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-86.png\" alt=\"\" class=\"wp-image-41220\" srcset=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-86.png 408w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-86-300x173.png 300w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/01\/image-86-150x86.png 150w\" sizes=\"auto, (max-width: 408px) 100vw, 408px\" \/><figcaption class=\"wp-element-caption\">Fluxograma de conduta com pacientes terminais. Fonte: Acervo de aulas do Grupo MedCof.<\/figcaption><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.grupomedcof.com.br\/cofletters\/?clientId=&amp;utm_campaign=newsletter&amp;utm_medium=banner&amp;utm_source=blog&amp;utm_content=inscricao#https:\/\/www.grupomedcof.com.br\/blog\/\" target=\"_blank\" rel=\" noreferrer noopener\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"320\" src=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-1024x320.png\" alt=\"\" class=\"wp-image-39227\" srcset=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-1024x320.png 1024w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-300x94.png 300w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-768x240.png 768w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-150x47.png 150w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-696x218.png 696w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-1068x334.png 1068w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1.png 1343w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-tratamento-do-carcinoma-nbsp\"><span class=\"ez-toc-section\" id=\"Tratamento_do_Carcinoma\"><\/span><strong>Tratamento do Carcinoma&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">O tratamento do CHC \u00e9 ditado pelo estadiamento<strong> BCLC (<em>Barcelona Clinic Liver Cancer<\/em>), <\/strong>que estratifica os pacientes n\u00e3o apenas pelo tumor, mas pela<strong> reserva funcional hep\u00e1tica <\/strong>e <strong>performance status.<\/strong> A complexidade do manejo reside no fato de que n\u00e3o tratamos apenas um tumor, mas tamb\u00e9m uma doen\u00e7a hep\u00e1tica cr\u00f4nica subjacente (cirrose) que limita nossas op\u00e7\u00f5es.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-terapias-curativas-estadios-0-e-a\"><span class=\"ez-toc-section\" id=\"Terapias_Curativas_Estadios_0_e_A\"><\/span><strong>Terapias Curativas (Est\u00e1dios 0 e A)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">O objetivo aqui \u00e9 a cura completa, com sobrevida esperada superior a 5-10 anos.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-a-resseccao-cirurgica-hepatectomia\"><strong>A. Ressec\u00e7\u00e3o Cir\u00fargica (Hepatectomia)<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c9 a primeira escolha para pacientes com fun\u00e7\u00e3o hep\u00e1tica preservada e tumor solit\u00e1rio. No entanto, \u00e9 a op\u00e7\u00e3o mais restritiva devido aos crit\u00e9rios de seguran\u00e7a rigorosos.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>O Candidato Ideal:<\/strong> Deve ter <strong>Child A<\/strong>, <strong>MELD<\/strong><strong> 8<\/strong> e, crucialmente, <strong>aus\u00eancia de Hipertens\u00e3o Portal<\/strong> clinicamente significativa.\n<ul class=\"wp-block-list\">\n<li><em>Crit\u00e9rio de Exclus\u00e3o:<\/em> A presen\u00e7a de varizes esof\u00e1gicas ou esplenomegalia com plaquetopenia (&lt; 100.000) geralmente contraindica a ressec\u00e7\u00e3o, pois o risco de descompensa\u00e7\u00e3o (ascite, fal\u00eancia hep\u00e1tica) no p\u00f3s-operat\u00f3rio \u00e9 proibitivo.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Margem e Remanescente:<\/strong> Busca-se margens livres com preserva\u00e7\u00e3o de pelo menos <strong>40-50%<\/strong> do par\u00eanquima hep\u00e1tico para evitar insufici\u00eancia hep\u00e1tica p\u00f3s-hepatectomia.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-b-transplante-hepatico-0\"><strong>B. Transplante Hep\u00e1tico<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c9 a terapia &#8220;perfeita&#8221; teoricamente, pois remove o tumor e cura a cirrose.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Crit\u00e9rios de Mil\u00e3o (O &#8220;Passaporte&#8221;):<\/strong>\n<ul class=\"wp-block-list\">\n<li>N\u00f3dulo \u00fanico <strong>5 cm<\/strong>.<\/li>\n\n\n\n<li>Ou at\u00e9 3 n\u00f3dulos, nenhum maior que <strong>3 cm<\/strong>.<\/li>\n\n\n\n<li><em>Nota:<\/em> N\u00f3dulos &lt; 2 cm podem ser desconsiderados na contagem inicial em alguns protocolos.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Prioriza\u00e7\u00e3o (MELD Especial):<\/strong> Para compensar o risco de <em>dropout<\/em> (tumor crescer e sair dos crit\u00e9rios enquanto espera), o paciente ganha pontos extras no MELD: inicia com 20, sobe para 24 em 3 meses e para 29 em 6 meses.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-c-ablacao-por-radiofrequencia-rfa-ou-micro-ondas\"><strong>C. Abla\u00e7\u00e3o por Radiofrequ\u00eancia (RFA) ou Micro-ondas<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Induz necrose tumoral t\u00e9rmica. \u00c9 considerada curativa para les\u00f5es pequenas.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indica\u00e7\u00e3o:<\/strong> N\u00f3dulos <strong>&lt; 3 cm<\/strong>, longe de grandes vasos (para evitar o <em>heat sink effect<\/em> &#8211; o sangue esfria a les\u00e3o e impede a abla\u00e7\u00e3o) e longe da via biliar principal.<\/li>\n\n\n\n<li><em>Posicionamento:<\/em> \u00c9 a escolha para Est\u00e1dio 0 (Muito Precoce) ou para pacientes Est\u00e1dio A n\u00e3o candidatos \u00e0 cirurgia.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-terapias-locorregionais-estadio-b-intermediario\"><span class=\"ez-toc-section\" id=\"Terapias_Locorregionais_Estadio_B_%E2%80%93_Intermediario\"><\/span><strong>Terapias Locorregionais (Est\u00e1dio B &#8211; Intermedi\u00e1rio)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Para o paciente com doen\u00e7a multinodular, mas restrita ao f\u00edgado e com fun\u00e7\u00e3o preservada.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Quimioemboliza\u00e7\u00e3o Transarterial (TACE)<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mecanismo:<\/strong> Cateterismo superseletivo da art\u00e9ria hep\u00e1tica que nutre o tumor. Injeta-se quimioter\u00e1pico + part\u00edculas embolizantes. O tumor sofre por <strong>isquemia<\/strong> (corta o suprimento) e <strong>citotoxicidade<\/strong> (droga local).<\/li>\n\n\n\n<li><strong>Resultados:<\/strong> Aumenta a sobrevida mediana para <strong>&gt; 26-30 meses<\/strong>.<\/li>\n\n\n\n<li><strong>Contraindica\u00e7\u00f5es:<\/strong> Trombose de veia porta (pois o fluxo portal \u00e9 o que mant\u00e9m o f\u00edgado n\u00e3o tumoral vivo ap\u00f3s a emboliza\u00e7\u00e3o arterial) e descompensa\u00e7\u00e3o hep\u00e1tica (Child C).<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-terapia-sistemica-estadio-c-avancado\"><span class=\"ez-toc-section\" id=\"Terapia_Sistemica_Estadio_C_%E2%80%93_Avancado\"><\/span><strong>Terapia Sist\u00eamica (Est\u00e1dio C &#8211; Avan\u00e7ado)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Reservada para doen\u00e7a extra-hep\u00e1tica ou invas\u00e3o vascular macrosc\u00f3pica.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-a-revolucao-da-imunoterapia\"><strong>A Revolu\u00e7\u00e3o da Imunoterapia<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">O padr\u00e3o-ouro mudou recentemente.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>1\u00aa Linha:<\/strong><strong>Atezolizumab<\/strong> (inibidor de checkpoint PD-L1) + <strong>Bevacizumab<\/strong> (anti-VEGF).\n<ul class=\"wp-block-list\">\n<li><em>Impacto:<\/em> Sobrevida global mediana superior a <strong>17 meses<\/strong>, superando o antigo padr\u00e3o.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>2\u00aa Linha (ou se contraindica\u00e7\u00e3o \u00e0 imunoterapia):<\/strong> Inibidores de tirosina quinase: <strong>Sorafenibe<\/strong> ou <strong>Lenvatinibe<\/strong> (Sobrevida de 12-15 meses).<\/li>\n\n\n\n<li><strong>3\u00aa Linha:<\/strong> Outros inibidores multiquinase (Regorafenibe, Cabozantinibe) ou novas imunoterapias.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-radioterapia-o-novo-jogador\"><span class=\"ez-toc-section\" id=\"Radioterapia_O_%E2%80%9CNovo%E2%80%9D_Jogador\"><\/span><strong>Radioterapia: O &#8220;Novo&#8221; Jogador<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Historicamente evitada por medo de toxicidade, a radioterapia moderna ganhou espa\u00e7o com tecnologias de precis\u00e3o.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SBRT (Stereotactic Body Radiation Therapy):<\/strong> Alta dose de radia\u00e7\u00e3o focal. \u00datil para les\u00f5es n\u00e3o pass\u00edveis de abla\u00e7\u00e3o ou TACE.<\/li>\n\n\n\n<li><strong>Radioemboliza\u00e7\u00e3o (TARE):<\/strong> Similar \u00e0 TACE, mas usa microesferas radioativas (\u00cdtrio-90) em vez de quimioterapia. Tem crescido como op\u00e7\u00e3o para casos&nbsp;<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"seja-um-medcofer\"><span class=\"ez-toc-section\" id=\"Seja_um_MedCofer\"><\/span><strong>Seja um MedCofer!<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Quer alcan\u00e7ar a aprova\u00e7\u00e3o nas provas de resid\u00eancia m\u00e9dica? Ent\u00e3o seja um&nbsp;<a href=\"https:\/\/www.grupomedcof.com.br\/home\/\"><strong>MedCofer<\/strong><\/a>! Aqui te ajudaremos na busca da aprova\u00e7\u00e3o com conte\u00fados de qualidade e uma metodologia que j\u00e1 aprovou mais de 35 mil residentes no pa\u00eds! Por fim, acesse o nosso<a href=\"https:\/\/www.youtube.com\/@GrupoMedcof\/featured\">&nbsp;<strong>canal do youtube&nbsp;<\/strong><\/a>para ver o nosso material.<\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<div class=\"youtube-embed\" data-video_id=\"a6cM6SWU5Xw\"><iframe loading=\"lazy\" title=\"Como fazer o diagn\u00f3stico de carcinoma hepatocelular?\" width=\"696\" height=\"392\" src=\"https:\/\/www.youtube.com\/embed\/a6cM6SWU5Xw?feature=oembed&#038;enablejsapi=1\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/div>\n<\/div><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>O Carcinoma Hepatocelular \u00e9 o tumor maligno prim\u00e1rio mais comum do f\u00edgado e a terceira principal causa de morte por c\u00e2ncer no mundo.<\/p>\n","protected":false},"author":21,"featured_media":41222,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[135],"tags":[],"ppma_author":[3617],"class_list":["post-41212","post","type-post","status-publish","format-standard","has-post-thumbnail","category-cirurgia-geral"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.6 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Carcinoma Hepatocelular: do rastreio ao transplante - Blog de Medcof: conte\u00fados, editais, revalida e mais!<\/title>\n<meta name=\"description\" content=\"O Carcinoma Hepatocelular \u00e9 o tumor maligno prim\u00e1rio mais comum do f\u00edgado e a terceira principal causa de morte por c\u00e2ncer no mundo.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Carcinoma Hepatocelular: do rastreio ao transplante\" \/>\n<meta property=\"og:description\" content=\"O Carcinoma Hepatocelular \u00e9 o tumor maligno prim\u00e1rio mais comum do f\u00edgado e a terceira principal causa de morte por c\u00e2ncer no mundo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog de Medcof: conte\u00fados, editais, revalida e mais!\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/MedCofQbank\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T14:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kiara Adelino\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kiara Adelino\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/carcinoma-hepatocelular\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/carcinoma-hepatocelular\\\/\"},\"author\":{\"name\":\"Kiara Adelino\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#\\\/schema\\\/person\\\/db19a651f86c5fc202d6eee744fd3292\"},\"headline\":\"Carcinoma Hepatocelular: do rastreio ao transplante\",\"datePublished\":\"2026-02-04T14:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/carcinoma-hepatocelular\\\/\"},\"wordCount\":1604,\"publisher\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/carcinoma-hepatocelular\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Blog-MedCof-2026-01-30T085452.509.jpg\",\"articleSection\":[\"Cirurgia Geral\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/carcinoma-hepatocelular\\\/\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/carcinoma-hepatocelular\\\/\",\"name\":\"Carcinoma Hepatocelular: do rastreio ao transplante - Blog de Medcof: conte\u00fados, editais, revalida e mais!\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/carcinoma-hepatocelular\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/carcinoma-hepatocelular\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Blog-MedCof-2026-01-30T085452.509.jpg\",\"datePublished\":\"2026-02-04T14:00:00+00:00\",\"description\":\"O Carcinoma Hepatocelular \u00e9 o tumor maligno prim\u00e1rio mais comum do f\u00edgado e a terceira principal causa de morte por c\u00e2ncer no mundo.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/carcinoma-hepatocelular\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/carcinoma-hepatocelular\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/carcinoma-hepatocelular\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Blog-MedCof-2026-01-30T085452.509.jpg\",\"contentUrl\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Blog-MedCof-2026-01-30T085452.509.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/carcinoma-hepatocelular\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Carcinoma Hepatocelular: do rastreio ao transplante\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/\",\"name\":\"Blog de Medcof: conte\u00fados, editais, revalida e mais!\",\"description\":\"Acesso o blog de MedCof! Seu portal de conte\u00fados sobre resid\u00eancia m\u00e9dica, an\u00e1lise e editais e muito mais. Clique e confira!\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#organization\"},\"alternateName\":\"Blog de Medcof: conte\u00fados, editais, revalida e mais!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#organization\",\"name\":\"Grupo MedCof\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/logo-medcof.png\",\"contentUrl\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/logo-medcof.png\",\"width\":768,\"height\":269,\"caption\":\"Grupo MedCof\"},\"image\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/MedCofQbank\\\/\",\"https:\\\/\\\/www.instagram.com\\\/grupomedcof\\\/\",\"https:\\\/\\\/br.linkedin.com\\\/company\\\/medcof\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCdHMuOHKICxcHwecxN8P-AA\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#\\\/schema\\\/person\\\/db19a651f86c5fc202d6eee744fd3292\",\"name\":\"Kiara Adelino\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/cropped-Kiara-Adelino2-96x96.jpega85663bdda67261f8f06f86e555e1e49\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/cropped-Kiara-Adelino2-96x96.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/cropped-Kiara-Adelino2-96x96.jpeg\",\"caption\":\"Kiara Adelino\"},\"description\":\"Estudante do 5\u00b0 semestre de Medicina. Gosto bastante de aprender coisas novas, principalmente na \u00e1rea de Neurologia e Anatomia humana.\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/author\\\/kiara-adelino\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Carcinoma Hepatocelular: do rastreio ao transplante - Blog de Medcof: conte\u00fados, editais, revalida e mais!","description":"O Carcinoma Hepatocelular \u00e9 o tumor maligno prim\u00e1rio mais comum do f\u00edgado e a terceira principal causa de morte por c\u00e2ncer no mundo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/","og_locale":"pt_BR","og_type":"article","og_title":"Carcinoma Hepatocelular: do rastreio ao transplante","og_description":"O Carcinoma Hepatocelular \u00e9 o tumor maligno prim\u00e1rio mais comum do f\u00edgado e a terceira principal causa de morte por c\u00e2ncer no mundo.","og_url":"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/","og_site_name":"Blog de Medcof: conte\u00fados, editais, revalida e mais!","article_publisher":"https:\/\/www.facebook.com\/MedCofQbank\/","article_published_time":"2026-02-04T14:00:00+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509.jpg","type":"image\/jpeg"}],"author":"Kiara Adelino","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Kiara Adelino","Est. tempo de leitura":"10 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#article","isPartOf":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/"},"author":{"name":"Kiara Adelino","@id":"https:\/\/www.grupomedcof.com.br\/blog\/#\/schema\/person\/db19a651f86c5fc202d6eee744fd3292"},"headline":"Carcinoma Hepatocelular: do rastreio ao transplante","datePublished":"2026-02-04T14:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/"},"wordCount":1604,"publisher":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/#organization"},"image":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#primaryimage"},"thumbnailUrl":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509.jpg","articleSection":["Cirurgia Geral"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/","url":"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/","name":"Carcinoma Hepatocelular: do rastreio ao transplante - Blog de Medcof: conte\u00fados, editais, revalida e mais!","isPartOf":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#primaryimage"},"image":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#primaryimage"},"thumbnailUrl":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509.jpg","datePublished":"2026-02-04T14:00:00+00:00","description":"O Carcinoma Hepatocelular \u00e9 o tumor maligno prim\u00e1rio mais comum do f\u00edgado e a terceira principal causa de morte por c\u00e2ncer no mundo.","breadcrumb":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#primaryimage","url":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509.jpg","contentUrl":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/02\/Blog-MedCof-2026-01-30T085452.509.jpg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.grupomedcof.com.br\/blog\/carcinoma-hepatocelular\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/www.grupomedcof.com.br\/blog\/"},{"@type":"ListItem","position":2,"name":"Carcinoma Hepatocelular: do rastreio ao transplante"}]},{"@type":"WebSite","@id":"https:\/\/www.grupomedcof.com.br\/blog\/#website","url":"https:\/\/www.grupomedcof.com.br\/blog\/","name":"Blog de Medcof: conte\u00fados, editais, revalida e mais!","description":"Acesso o blog de MedCof! Seu portal de conte\u00fados sobre resid\u00eancia m\u00e9dica, an\u00e1lise e editais e muito mais. Clique e confira!","publisher":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/#organization"},"alternateName":"Blog de Medcof: conte\u00fados, editais, revalida e mais!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.grupomedcof.com.br\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/www.grupomedcof.com.br\/blog\/#organization","name":"Grupo MedCof","url":"https:\/\/www.grupomedcof.com.br\/blog\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.grupomedcof.com.br\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2022\/01\/logo-medcof.png","contentUrl":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2022\/01\/logo-medcof.png","width":768,"height":269,"caption":"Grupo MedCof"},"image":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/MedCofQbank\/","https:\/\/www.instagram.com\/grupomedcof\/","https:\/\/br.linkedin.com\/company\/medcof","https:\/\/www.youtube.com\/channel\/UCdHMuOHKICxcHwecxN8P-AA"]},{"@type":"Person","@id":"https:\/\/www.grupomedcof.com.br\/blog\/#\/schema\/person\/db19a651f86c5fc202d6eee744fd3292","name":"Kiara Adelino","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2024\/08\/cropped-Kiara-Adelino2-96x96.jpega85663bdda67261f8f06f86e555e1e49","url":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2024\/08\/cropped-Kiara-Adelino2-96x96.jpeg","contentUrl":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2024\/08\/cropped-Kiara-Adelino2-96x96.jpeg","caption":"Kiara Adelino"},"description":"Estudante do 5\u00b0 semestre de Medicina. Gosto bastante de aprender coisas novas, principalmente na \u00e1rea de Neurologia e Anatomia humana.","url":"https:\/\/www.grupomedcof.com.br\/blog\/author\/kiara-adelino\/"}]}},"authors":[{"term_id":3617,"user_id":21,"is_guest":0,"slug":"kiara-adelino","display_name":"Kiara Adelino","avatar_url":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2024\/08\/cropped-Kiara-Adelino2-96x96.jpeg","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/posts\/41212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/comments?post=41212"}],"version-history":[{"count":2,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/posts\/41212\/revisions"}],"predecessor-version":[{"id":41224,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/posts\/41212\/revisions\/41224"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/media\/41222"}],"wp:attachment":[{"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/media?parent=41212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/categories?post=41212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/tags?post=41212"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/ppma_author?post=41212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}